Cancer - Fog Pharmaceuticals, Inc.

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05919264

A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors

Drug

FOG-001

Condition

Advanced or Metastatic Solid Tumors